Compounds > aspirin

aspirin and regorafenib

aspirin has been researched along with regorafenib in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Andrikou, K; Berardi, R; Bianconi, M; Bittoni, A; Cabras, F; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Maccaroni, E; Pusceddu, V; Restivo, A; Scartozzi, M; Scintu, F; Zorcolo, L1
Astara, G; Bernardini, L; Casadei-Gardini, A; Cascinu, S; D'Amico, FE; Dadduzio, V; Fornaro, L; Lai, E; Lonardi, S; Masi, G; Pretta, A; Rimini, M; Rovesti, G; Scartozzi, M; Vivaldi, C; Zagonel, V1
Matoba, S; Ookura, T; Shoji, K; Yanishi, K; Zen, K1

Other Studies

3 other study(ies) available for aspirin and regorafenib

ArticleYear
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy.
    Clinical colorectal cancer, 2017, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Capecitabine; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine; Uracil

2017
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2021, Volume: 23, Issue:6

    Topics: Antineoplastic Agents; Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome

2021
Early stent thrombosis confirmed in a cancer patient receiving regorafenib, despite triple antithrombotic therapy: a case report.
    BMC cardiovascular disorders, 2021, 01-30, Volume: 21, Issue:1

    Topics: Aged; Angiogenesis Inhibitors; Aspirin; Colorectal Neoplasms; Coronary Artery Disease; Coronary Thrombosis; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Fatal Outcome; Fibrinolytic Agents; Humans; Male; Percutaneous Coronary Intervention; Phenylurea Compounds; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridines; Pyridones; Risk Factors; Stents; Treatment Outcome; Venous Thrombosis

2021